KR-33493 is a FAS-associated factor 1 (FAF1) inhibitor and can be used in studies about Parkinson's disease.

Araloside A (Chikusetsusaponin IV) might relieve cutaneous symptoms caused by excessive apoptotic cell death in the skin through the Fas/FasL pathway.

Kp7-6 is a Fas mimetic peptide that disrupts receptor complexes by simultaneously binding to Fas and FasL, thereby blocking downstream apoptotic signaling. Kp7-6 inhibits ERK1-2 phosphorylation, induces IκBα phosphorylation, and activates NF-κB. Kp7-6 suppresses the activation of caspase-8, caspase-3, and JNK, reduces human amylin-induced β-cell apoptosis, and decreases FasL-mediated lymphocyte cytotoxicity and apoptosis. In pancreatic neuroendocrine tumor models, Kp7-6 downregulates local FasL expression, increases CD8+Fas+ T-cell infiltration, and reduces tumor volume. Kp7-6 prevents concanavalin A-induced liver injury in mice and is applicable to research on type 2 diabetes, hepatitis, and pancreatic neuroendocrine tumors.

Marginatoxin may be a promising chemopreventive agent for treating hepatocellular carcinoma, it induces human hepatoma BEL-7402 cells apoptosis in vitro and in vivo via activation of Fas/FasL-mediated apoptotic pathway.